1. Patricia Brown, PhD, ARNP Where Are We Heading?

4. New ADTs This Decade o Oleptro (extended release Trazodone) 2010 o Viibryd (Vilazodone) 2011 o Fetzima (Levomilnacipran) 2013 o Brintellix (Vortioxetine) 2013

7. 313 Psychiatric Drugs in Development o Dementia (90 Investigational Products) o Depression (71 Investigational Products ) o Schizophrenia (54 Investigational Products) o Anxiety Disorders (38 Investigational Products)

8. The NIMH Priority for Psychiatric Drug Development: o Rapid acting antidepressant o Generation of antipsychotics which assists with cognition o Autism medication which addresses pro- social components

9. Ketamine infusions for treatment resistant depression

11. ALKS 5461

13. Blocking the Kappa Receptor o When Dynorphin are released=Depression o Blocking this stimulates ADT action o High levels of Dynorphin block glutamate. Glutamate is thought to prevent neuroplasticity and prevent poor learning abilities and prevent learned helplessness.

14.  AVP-786 is a modified dextromethorphan which is an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter

16. As of Jan 2015 There Are 5 New Anxiety Investigation Products o Most popular drug still are BDZs o The goal –to find as efficacious a drug without the sedative side effects or addictive potential

17. Aloradine (PH94B) o A vomeropherine neuroactive steriod drug o Under development as a nasal spray formulation o For the acute treatment of social anxiety disorder in women.

18. B-GOS o Galacto-oligosaccharides belong to the group of prebiotics. o Prebiotics are defined as non-digestible food ingredients that beneficially affect the host by stimulating the growth and/or activity of beneficial bacteria in the colon.

19. IW-2143 (BNC210)

20. S32212 o a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant

21. SL-651,498 o a GABAA receptor agonist with subtype- selective efficacy, as a potential treatment for generalized anxiety disorder o an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.

22. Translocator Protein (18 kD) o Peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state.

23. TMS

24. Over 30 New Medications in Development for Schizophrenia May 2014

27. Caripazine (RGH-188) o D2, D3 antagonist

28. LY2140023 o Prodrug for an mGluR2/3 agonist o Phase three development

29. Brexpiprazole OPC-34712 o a novel D2 dopamine partial agonist

32. What is in the works for Cognition and social skill development in autism

33. Autism Drugs in Development o AT001 ( uoxetine rapid dissolve) ORPHAN DRUG o CM-AT Rye, NY (Fast Track) application submitted www.curemark.comwww.curemark.com o CNDO-201 (Trichuris suis ova) Coronado Biosciences autism Phase II www.coronadobiosciences.com o Memantine Forest Laboratories Phase II completed o RG7314 (vasopressin-1 receptor antagonist) o Autism Phase II o Syntocinon nasal spray Retrophin Arbaclofen or STX209, is a derivative of the FDA-approved drug, baclofen

34. NIMH Strategic Objectives o Promote discovery in the brain and behavioral sciences to fuel research on the causes of mental disorders o Chart mental illness trajectories to determine when, where and how to intervene o Develop new and better interventions that incorporate the diverse needs and circumstances of people with mental illnesses o Strengthen the public health impact of NIMH- supported research

36. o Thank You for Your Attention!

37. References o Huda Akil, Sydney Brenner, Eric Kandel, Kenneth S. Kendler, Mary-Claire King, Edward Scolnick, James D. Watson, and Huda Y. Zoghbi; The Future of Psychiatric Research: Genomes and Neural Circuits. Science 26 March 2010: 1580-1581. o Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie, Charles C. Persinger, Bernard H. Munos, Stacy R. Lindborg, Aaron L. Schacht ; How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 9, 203-214 (19 February 2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge